Cargando…
Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa
Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the poten...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769688/ https://www.ncbi.nlm.nih.gov/pubmed/36301146 http://dx.doi.org/10.1128/spectrum.02232-22 |
_version_ | 1784854425868697600 |
---|---|
author | Macho, Markéta Saha, Subhasish Konert, Grzegorz Banerjee, Avik Ewe, Daniela Hrouzek, Pavel Urajová, Petra Saurav, Kumar |
author_facet | Macho, Markéta Saha, Subhasish Konert, Grzegorz Banerjee, Avik Ewe, Daniela Hrouzek, Pavel Urajová, Petra Saurav, Kumar |
author_sort | Macho, Markéta |
collection | PubMed |
description | Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen’s ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use. |
format | Online Article Text |
id | pubmed-9769688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-97696882022-12-22 Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa Macho, Markéta Saha, Subhasish Konert, Grzegorz Banerjee, Avik Ewe, Daniela Hrouzek, Pavel Urajová, Petra Saurav, Kumar Microbiol Spectr Observation Resistance development and exhaustion of the arsenal of existing antibacterial agents urgently require an alternative approach toward drug discovery. Herein, we report the screening of Medicines for Malaria Venture (MMV) Pandemic Response Box (PRB) through a cascade developed to streamline the potential compounds with antivirulent properties to combat an opportunistic pathogen, Pseudomonas aeruginosa. To find an agent suppressing the production of P. aeruginosa virulence factors, we assessed the potential of the compounds in PRB with quorum sensing inhibitory activity. Our approach led us to identify four compounds with significant inhibition of extracellular virulence factor production and biofilm formation. This provides an opportunity to expand and redirect the application of these data sets toward the development of a drug with unexplored target-based activity. IMPORTANCE The rise of drug-resistant pathogens as well as overuse and misuse of antibiotics threatens modern medicine as the number of effective antimicrobial drugs steadily decreases. Given the nature of antimicrobial resistance development under intense selective pressure such as the one posed by pathogen-eliminating antibiotics, new treatment options which could slow down the emergence of resistance are urgently needed. Antivirulence therapy aims at suppressing a pathogen’s ability to cause disease rather than eliminating it, generating significantly lower selective pressure. Quorum sensing inhibitors are thought to be able to downregulate the production of virulence factors, allowing for smaller amounts of antimicrobials to be used and thus preventing the emergence of resistance. The PRB constitutes an unprecedented opportunity to repurpose new as well as known compounds with cytotoxicity and in vitro absorption, distribution, metabolism and excretion (ADME) profile available, thus shortening the time between compound discovery and medicinal use. American Society for Microbiology 2022-10-27 /pmc/articles/PMC9769688/ /pubmed/36301146 http://dx.doi.org/10.1128/spectrum.02232-22 Text en Copyright © 2022 Macho et al. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Observation Macho, Markéta Saha, Subhasish Konert, Grzegorz Banerjee, Avik Ewe, Daniela Hrouzek, Pavel Urajová, Petra Saurav, Kumar Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title | Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title_full | Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title_fullStr | Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title_full_unstemmed | Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title_short | Screening of the Medicines for Malaria Venture Pandemic Response Box for Discovery of Antivirulent Drug against Pseudomonas aeruginosa |
title_sort | screening of the medicines for malaria venture pandemic response box for discovery of antivirulent drug against pseudomonas aeruginosa |
topic | Observation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769688/ https://www.ncbi.nlm.nih.gov/pubmed/36301146 http://dx.doi.org/10.1128/spectrum.02232-22 |
work_keys_str_mv | AT machomarketa screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT sahasubhasish screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT konertgrzegorz screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT banerjeeavik screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT ewedaniela screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT hrouzekpavel screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT urajovapetra screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa AT sauravkumar screeningofthemedicinesformalariaventurepandemicresponseboxfordiscoveryofantivirulentdrugagainstpseudomonasaeruginosa |